Pomegra
Washington State startup Resect AI launched from stealth September 3 with $25 million in seed funding to build a real-time accountability layer that stops AI hallucinations inside the model, not after.
- Resect AI raised $25M in seed funding from undisclosed private equity investors; no valuation was attached to the round.
- Unlike post-hoc evaluation tools, Resect's patented system intervenes during text generation by monitoring and modifying internal model behavior in real time.
- The company employs 30 people across five states and targets 50 hires by end of 2026.
Lead
Resect AI, headquartered in Washougal, Washington - a small Columbia River town across from Portland - emerged from stealth on September 3, 2026, with $25 million in seed funding. The company is commercializing a patented approach to LLM hallucination prevention that it says operates inside the model during generation, targeting enterprise sectors including finance, healthcare, publishing, and research. No lead investor was named, and no post-money valuation was disclosed, both omissions unusual at this funding size.
What Does Resect AI Actually Build?
The core claim separating Resect from a crowded field of AI monitoring vendors is timing. Most hallucination-mitigation tools in production today work as output filters: they score or fact-check text after a model has already generated it. Resect's system, which it calls the NeuroWave Product Suite, operates in-stream - monitoring the internal states of a large language model as it generates tokens, detecting the behavioral signatures the company associates with fabrication, and modifying outputs before they leave the model. The company describes the product as "a polygraph for neural networks."
The approach is patented, though the underlying technical method has not been independently verified or peer-reviewed in any publicly available form. Whether the system performs reliably across model families and deployment environments at enterprise scale remains an open question that customer production data will eventually answer.
Why Is the Investor Silence Notable?
A $25 million seed round with no named lead investor is an atypical structure. The company disclosed only that funding came from private equity sources. In most technology seed rounds of this size, at least one institutional backer attaches their name - in part to signal validation and in part for their own deal visibility. The decision not to disclose investor identity could reflect mutual preference for quiet positioning ahead of commercial traction, but it also removes a common market signal that enterprise buyers use when evaluating vendor durability.
No valuation was attached to the round. That figure matters because it sets expectations for the next raise; without it, the company's implied price-to-progress ratio remains opaque.
How Does Resect's Approach Differ From Competitors?
The AI reliability and observability market already includes several well-capitalized players offering post-generation evaluation, retrieval-augmented generation guardrails, and output scoring layers. Resect's bet is that intervening before output - inside model inference - is both more effective and more auditable than catching errors downstream.
That bet is not trivial to execute. In-stream intervention during inference requires access to model internals at a level that most enterprise deployments restrict. The pitch works cleanly with open-weight models where activation-level access is possible; it is less obvious how the architecture applies to models accessed only through API endpoints, where the internals are a black box. The company has not publicly addressed that deployment constraint.
The audit trail component - producing compliance-grade records of what the model considered and how behavior was modified - is the more immediately legible enterprise value proposition, particularly for financial services and healthcare buyers facing AI governance requirements.
Team and Operations
Resect AI's three co-founders hold operating titles: Tim Walton as chief AI officer, Tyler Gerber as chief operating officer, and Tommy Lofgren as chief product and marketing officer. Four of the company's 30 employees work out of the Washougal headquarters office on Main Street; the remainder are distributed across the Seattle area, California, New York, and Texas. The company plans to reach 50 employees before year-end, with hiring focused on the greater Seattle and Portland markets.
Outlook
The $25 million gives Resect enough runway to move from commercializing a research-stage system to landing and expanding enterprise accounts. The real test is whether in-stream intervention at the model level proves deployable across the diverse infrastructure configurations that large enterprise customers actually run. If the NeuroWave suite delivers measurable hallucination reduction in production - not just in controlled demos - the company will have a defensible wedge in a market where reliability is becoming table stakes. If it cannot, the audit-trail and AI accountability framing will need to carry the load on its own.
